What is an efficient health intervention in Spain in 2020?

被引:61
作者
Antonio Sacristan, Jose [1 ,2 ]
Oliva, Juan [3 ]
Campillo-Artero, Carlos [4 ,5 ]
Puig-Junoy, Jaume [4 ]
Luis Pinto-Prades, Jose [6 ]
Dilla, Tatiana [2 ,7 ]
Rubio-Terres, Carlos [8 ]
Ortun, Vicente [4 ]
机构
[1] Univ Autonoma Madrid, Fac Med, Dept Epidemiol & Salud Publ, Madrid, Spain
[2] Lilly Espana, Dept Med, Madrid, Spain
[3] Univ Castilla La Mancha, Fac Ciencias Jurid & Sociales, Dept Anal Econ & Finanzas, Toledo, Spain
[4] Univ Pompeu Fabra, Barcelona Sch Management, Barcelona, Spain
[5] Serv Salut Illes Balears, Palma De Mallorca, Spain
[6] Univ Navarra, Dept Econ, Pamplona, Spain
[7] Univ Carlos III, Evaluac & Acceso Mercado, Madrid, Spain
[8] Hlth Value, Madrid, Spain
关键词
Efficiency; Cost-effectiveness; Threshold; Economic evaluation; Health technology; Pharmaceuticals; Price; Financing; COST-EFFECTIVENESS THRESHOLD; LIFE; MCDA;
D O I
10.1016/j.gaceta.2019.06.007
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Fifteen years ago, GACETA SANITARIA published the article entitled "What is an efficient health technology in Spain?"The growing interest in setting the price of new technologies based on the value they provide to health systems and the experience accumulated by the countries in our environment make it opportune to review what constitutes an efficient health intervention in Spain in 2020. Cost-effectiveness analysis continues to be the reference method to maximize social health outcomes with the available resources. The interpretation of its results requires establishing reference values that serve as a guide on what constitutes a reasonable value for the health care system. Efficiency thresholds must be flexible and dynamic, and they need to be updated periodically. Its application should be based on and transparency, and consider other factors that reflect social preferences. Although setting thresholds is down to political decision-makers, in Spain it could be reasonable to use thresholds of 25,000 and 60,000 Euros per QALY. However, currently, in addition to determining exact figures for the threshold, the key question is whether the Spanish National Health System is able and willing to implement a payment model based on value, towards achieving gradual financing decisions and, above all, to improve the predictability, consistency and transparency of the process. (C) 2019 SESPAS. Published by Elsevier Espana, S.L.U.
引用
收藏
页码:189 / 193
页数:5
相关论文
共 32 条
  • [1] Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework
    Angelis, Aris
    Kanavos, Panos
    [J]. SOCIAL SCIENCE & MEDICINE, 2017, 188 : 137 - 156
  • [2] [Anonymous], [No title captured]
  • [3] [Anonymous], [No title captured]
  • [4] [Anonymous], [No title captured]
  • [5] [Anonymous], [No title captured]
  • [6] What does the value of modern medicine say about the $50,000 per Quality-Adjusted Life-Year decision rule?
    Braithwaite, R. Scott
    Meltzer, David O.
    King, Joseph T., Jr.
    Leslie, Douglas
    Roberts, Mark S.
    [J]. MEDICAL CARE, 2008, 46 (04) : 349 - 356
  • [7] When is it too expensive? Cost-effectiveness thresholds and health care decision-making
    Brouwer, Werner
    van Baal, Pieter
    van Exel, Job
    Versteegh, Matthijs
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2019, 20 (02) : 175 - 180
  • [8] On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review
    Cameron, David
    Ubels, Jasper
    Norstrom, Fredrik
    [J]. GLOBAL HEALTH ACTION, 2018, 11 (01):
  • [9] Does MCDA Trump CEA?
    Campillo-Artero, Carlos
    Puig-Junoy, Jaume
    Culyer, Anthony J.
    [J]. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2018, 16 (02) : 147 - 151
  • [10] Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists
    Camps-Herrero, C.
    Paz-Ares, L.
    Codes, M.
    Lopez-Lopez, R.
    Anton-Torres, A.
    Gason-Vilaplana, P.
    Guillem-Porta, V.
    Carrato, A.
    Cruz-Hernandez, J. J.
    Caballero-Diaz, C.
    Blasco-Cordellat, A.
    Moreno-Nogueira, J. A.
    Diaz-Rubio, E.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2014, 16 (10) : 914 - 920